Hey everyone! Hope you’re all having a great week so far.
Check out the latest podcast episode here. In episode 50, Michael and I discuss updates on Roche and Genentech’s experimental therapy risdiplam. Now that this drug is under FDA-approval, we answer questions regarding its potential cost, and what kind of impact it will have on the SMA community.
We also talk about two of our recent columns from our main site. The first is about media representation of people with disabilities; and the second, written by parent columnist Michael Casten, is about working through life’s frustrations. Listen here, and share your thoughts in our forums.
Hope you all enjoy! For more conversations and interviews, check out the podcast archives here.
Do you have any takeaways from this episode? Do you have any questions regarding risdiplam?
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.